Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „abatacept“
Suchtreffer
Begriffe & Kennungen
Orencia · 4.8 · Acute infusion-related events that were reported in > 0.1% and ≤ 1% of patients treated with abatacept include
Eintrag öffnenOrencia · 4.8 · Autoimmune processes Abatacept therapy did not lead to increased formation of autoantibodies, i.e., antinuclea
Eintrag öffnenOrencia · 4.8 · Autoimmune processes Abatacept therapy did not lead to increased formation of autoantibodies, i.e., antinuclea
Eintrag öffnenOrencia · 4.8 · Autoimmune processes Abatacept therapy did not lead to increased formation of autoantibodies, i.e., antinuclea
Eintrag öffnenOrencia · 4.8 · Discontinuation due to an acute infusion-related reaction occurred in 0.3% of patients receiving abatacept and
Eintrag öffnenOrencia · 4.8 · Immunogenicity Antibodies directed against the abatacept molecule were assessed by ELISA assays in 3,985 rheum
Eintrag öffnenOrencia · 4.8 · Immunogenicity Antibodies directed against the entire abatacept molecule or to the CTLA-4 portion of abatacept
Eintrag öffnenOrencia · 4.8 · Immunogenicity and safety of abatacept upon withdrawal and restart of treatment A study in the subcutaneous pr
Eintrag öffnenOrencia · 4.8 · Immunogenicity and safety of abatacept upon withdrawal and restart of treatment A study in the subcutaneous pr
Eintrag öffnenOrencia · 4.8 · Immunogenicity in adults treated with subcutaneous abatacept Study SC-I compared the immunogenicity to abatace
Eintrag öffnenOrencia · 4.8 · Immunogenicity in adults treated with subcutaneous abatacept Study SC-I compared the immunogenicity to abatace
Eintrag öffnenOrencia · 4.8 · Immunogenicity to abatacept following long-term subcutaneous administration was assessed by a new electrochemi
Eintrag öffnenOrencia · 4.8 · Immunogenicity to abatacept following long-term subcutaneous administration was assessed by a new electrochemi
Eintrag öffnenOrencia · 4.8 · In placebo-controlled clinical trials with abatacept, adverse reactions (ARs) were reported in 49.4% of abatac
Eintrag öffnenOrencia · 4.8 · In placebo-controlled clinical trials with abatacept, adverse reactions (ARs) were reported in 49.4% of abatac
Eintrag öffnenOrencia · 4.8 · In placebo-controlled clinical trials with abatacept, adverse reactions (ARs) were reported in 49.4% of abatac
Eintrag öffnenOrencia · 4.8 · In study SC-III, similar immunogenicity rates were seen in patients on treatment for the abatacept+MTX, and ab
Eintrag öffnenOrencia · 4.8 · In study SC-III, similar immunogenicity rates were seen in patients on treatment for the abatacept+MTX, and ab
Eintrag öffnenOrencia · 4.8 · In the cumulative period 7,044 patients treated with abatacept during 21,011 patient-years (of which over 1,00
Eintrag öffnenOrencia · 4.8 · In the cumulative period 7,044 patients treated with abatacept during 21,011 patient-years (of which over 1,00
Eintrag öffnen